- Commissioner Enhances FDA’s Commitment to Personalized Medicine
- Perfecting Policy on Stem Cells
- NIH and FDA Aim to Retool Regulatory Science
- DOE Leads Federal Funding for a Regional Innovation Cluster
- Certainty on the Science of Climate Change
- They’re Not Perfect Cells, But They’re Model Cells
- Genomic Medicine on the March
- President’s Budget Aims to Recharge Regional Innovation
- Event: The Science of Climate Change
- Progress in Bioethics
- The Top Science Progress Features of 2009
- Science Education Progress
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
- January 2008
- December 2007
- November 2007
- October 2007
- September 2007
This Week In HIV/AIDS News
New research from the University of Texas and University College London, published yesterday in the journal Cell Host & Microbe, suggests that a mutation in the Duffy antigen, or DARC, present on red blood cells may increase an individual’s chances of contracting HIV by 40 percent. The mutation spread over the course of several millennia in Africa and confers resistance to the world’s most prevalent malarial strain, but one that is no longer a serious threat to that continent.
According to the research, 90 percent of the African population express two copies of a mutation in DARC called DARC-negative. This mutation effectively removes the Duffy antigen from the surface of red blood cells, where it would normally bind to chemokines, small molecules that contribute to the immune response. Antigens like Duffy are large molecules that help generate antibodies and increase the response of the immune system.
However, the new study suggests that the mutated Duffy antigen that is so common in the African population actually helps the HIV virus attach to red blood cells, and more efficiently infect T cells. T cells are like the police chiefs of the immune system—they activate other cells and tell them to destroy various biological threats, such as cells that have been infected by viruses. Once T cells get infected by HIV, the body’s ability to destroy other cells infected by the virus is severely compromised.
But the DARC mutation is not completely devastating for those at risk of contracting HIV. The study indicates that “DARC-negative… is associated with slower disease progression.” In other words, HIV spreads slower when the body’s immune system is already slightly compromised by the mutation in DARC. So while individuals who are DARC negative are at a greater risk for contracting HIV, the same mutation may also slow the progression of the disease.
This research news comes just after the House and Senate passed bills allocating $50 billion for the global fight against AIDS and other diseases and lifting a travel ban for HIV-positive people that has been in place since 1987. However, this latest work on the mutation suggests that policymakers should also increase their commitment to funding HIV/AIDS research, especially because of further discouragement within the community about the possibilities for the development of a vaccine.
Comments on this article


